These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 32728833)

  • 21. Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog
    Leohr J; Dellva MA; Coutant DE; LaBell E; Heise T; Andersen G; Zijlstra E; Hermanski L; Nosek L; Linnebjerg H
    Clin Pharmacokinet; 2020 Dec; 59(12):1601-1610. PubMed ID: 32468448
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog
    Linnebjerg H; Zhang Q; LaBell E; Dellva MA; Coutant DE; Hövelmann U; Plum-Mörschel L; Herbrand T; Leohr J
    Clin Pharmacokinet; 2020 Dec; 59(12):1589-1599. PubMed ID: 32468447
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ultra rapid lispro showed greater reduction in postprandial glucose versus Humalog in children, adolescents and adults with type 1 diabetes mellitus.
    Aronson R; Biester T; Leohr J; Pollom R; Linnebjerg H; LaBell ES; Zhang Q; Coutant DE; Danne T
    Diabetes Obes Metab; 2023 Jul; 25(7):1964-1972. PubMed ID: 36974352
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ultra-Rapid Lispro results in accelerated insulin lispro absorption and faster early insulin action in comparison with Humalog
    Shiramoto M; Nasu R; Oura T; Imori M; Ohwaki K
    J Diabetes Investig; 2020 May; 11(3):672-680. PubMed ID: 31816193
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ultra rapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogues: A phase 1 randomized, crossover study.
    Heise T; Linnebjerg H; Coutant D; LaBell E; Zijlstra E; Kapitza C; Bue-Valleskey J; Zhang Q; Dellva MA; Leohr J
    Diabetes Obes Metab; 2020 Oct; 22(10):1789-1798. PubMed ID: 32436641
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased Time in Range with Ultra Rapid Lispro Treatment in Participants with Type 2 Diabetes: PRONTO-Time in Range.
    Bailey TS; Bode BW; Wang Q; Knights AW; Chang AM
    Diabetes Ther; 2023 May; 14(5):883-897. PubMed ID: 37029268
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ultra Rapid Lispro (URLi) Accelerates Insulin Lispro Absorption and Insulin Action vs Humalog
    Leohr J; Dellva MA; Carter K; LaBell E; Linnebjerg H
    Clin Pharmacokinet; 2021 Nov; 60(11):1423-1434. PubMed ID: 34041713
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ultra rapid lispro (Lyumjev®) shortens time to recovery from hyperglycaemia compared to Humalog® in individuals with type 1 diabetes on continuous subcutaneous insulin infusion.
    Leohr J; Dellva MA; LaBell E; Coutant DE; Arrubla J; Plum-Mörschel L; Zijlstra E; Fukuda T; Hardy T
    Diabetes Obes Metab; 2024 Jan; 26(1):215-223. PubMed ID: 37814517
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of insulin glulisine in Japanese patients with type 1 diabetes mellitus.
    Kawamori R; Kadowaki T; Ishii H; Iwasaki M; Iwamoto Y
    Diabetes Obes Metab; 2009 Sep; 11(9):891-9. PubMed ID: 19614947
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fasting and postprandial plasma glucose contributions to hemoglobin A1c and time in range in people with diabetes on multiple daily injection insulin therapy: Results from the PRONTO-T1D and PRONTO-T2D clinical trials.
    Piras de Oliveira C; Dellva MA; Bue-Valleskey J; Chang AM; Liao B
    J Diabetes Complications; 2024 Jan; 38(1):108648. PubMed ID: 38035641
    [TBL] [Abstract][Full Text] [Related]  

  • 31. What is the value of faster acting prandial insulin? Focus on ultra rapid lispro.
    Heise T; Piras de Oliveira C; Juneja R; Ribeiro A; Chigutsa F; Blevins T
    Diabetes Obes Metab; 2022 Sep; 24(9):1689-1701. PubMed ID: 35593434
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
    Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G
    Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multicenter Evaluation of Ultra-Rapid Lispro Insulin with Control-IQ Technology in Adults, Adolescents, and Children with Type 1 Diabetes.
    Levy CJ; Bailey R; Laffel LM; Forlenza G; DiMeglio LA; Hughes MS; Brown SA; Aleppo G; Bhargava A; Shah VN; Clements MA; Kipnes M; Bruggeman B; Daniels M; Rodriguez H; Calhoun P; Lum JW; Sasson-Katchalski R; Pinsker JE; Pollom R; Beck RW;
    Diabetes Technol Ther; 2024 Sep; 26(9):652-660. PubMed ID: 38696672
    [No Abstract]   [Full Text] [Related]  

  • 34. Pharmacokinetic and Glucodynamic Responses of Ultra Rapid Lispro vs Lispro Across a Clinically Relevant Range of Subcutaneous Doses in Healthy Subjects.
    Leohr J; Dellva MA; LaBell E; Coutant DE; Klein O; Plum-Moerschel L; Zijlstra E; Linnebjerg H
    Clin Ther; 2020 Sep; 42(9):1762-1777.e4. PubMed ID: 32900535
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and Safety of Biosimilar SAR342434 Insulin Lispro in Adults with Type 1 Diabetes Also Using Insulin Glargine-SORELLA 1 Study.
    Garg SK; Wernicke-Panten K; Rojeski M; Pierre S; Kirchhein Y; Jedynasty K
    Diabetes Technol Ther; 2017 Sep; 19(9):516-526. PubMed ID: 28722480
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of a premixed versus a basal-plus insulin regimen as intensification for type 2 diabetes by timing of the main meal.
    Gross JL; Rojas A; Shah S; Tinahones FJ; Cleall S; Rodríguez A
    Curr Med Res Opin; 2016 Jun; 32(6):1109-16. PubMed ID: 26934128
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of Efficacy and Economic Value of Prandilin 25 and Humalog Mix 25 in Patients with Newly Diagnosed Type 2 Diabetes by a Continuous Glucose Monitoring System.
    Luo Y; Wang XQ; Ni WJ; Ding B; Xu XH; Ye L; Ma JH; Zhu J
    Diabetes Ther; 2018 Dec; 9(6):2219-2228. PubMed ID: 30244319
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Insulin lispro 25/75 and insulin lispro 50/50 as starter insulin in Japanese patients with type 2 diabetes: subanalysis of the CLASSIFY randomized trial.
    Watada H; Imori M; Li P; Iwamoto N
    Endocr J; 2017 Jul; 64(7):705-717. PubMed ID: 28539526
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rapid-Acting Insulin Analogues Versus Regular Human Insulin: A Meta-Analysis of Effects on Glycemic Control in Patients with Diabetes.
    Nicolucci A; Ceriello A; Di Bartolo P; Corcos A; Orsini Federici M
    Diabetes Ther; 2020 Mar; 11(3):573-584. PubMed ID: 31873857
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
    Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.